Pamir Ozan 4
4 · Niagen Bioscience, Inc. · Filed Nov 17, 2025
Insider Transaction Report
Form 4
Pamir Ozan
Chief Financial Officer
Transactions
- Purchase
Common Stock
2025-11-14$6.81/sh+4,464.962$30,406→ 7,372.159 total - Purchase
Common Stock
2025-11-14$6.85/sh+2,220.443$15,210→ 2,220.443 total(indirect: By Spouse)
Footnotes (1)
- [F1]The weighted average purchase price for the transaction reported was $6.81, and the range of prices were between $6.7975 and $6.82, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided.